PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Euronext Amsterdam
|
||
| - EUR | - |
|
| Market Cap | 891M 810M 748M 676M 1.28B 83.68B 1.32B 9B 3.56B 44.9B 3.34B 3.27B 142B | P/E 2026 * |
41x | P/E 2027 * | 33.4x |
|---|---|---|---|---|---|
| Enterprise Value | 836M 760M 702M 634M 1.2B 78.54B 1.24B 8.44B 3.35B 42.15B 3.14B 3.07B 134B | EV / Sales 2026 * |
2.16x | EV / Sales 2027 * | 1.84x |
| Free-Float |
98.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
Kenneth Lynard
CEO | Chief Executive Officer | 58 | 29/09/2026 |
Leverne Marsh
CEO | Chief Executive Officer | - | 29/09/2026 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/06/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 11/12/2020 |
Mark Pykett
BRD | Director/Board Member | 62 | 11/12/2020 |
| Director/Board Member | 60 | 19/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.17% | +2.59% | +41.77% | +146.03% | 1,286B | ||
| -0.19% | +1.03% | +42.80% | +89.88% | 688B | ||
| +0.59% | +1.24% | +26.90% | +114.75% | 521B | ||
| +1.14% | +2.04% | +42.51% | +72.81% | 386B | ||
| -0.80% | -1.33% | +58.06% | +43.91% | 364B | ||
| +1.27% | +1.72% | +28.34% | +63.11% | 302B | ||
| +0.37% | -0.23% | +3.25% | +38.05% | 287B | ||
| +0.58% | +0.71% | +37.12% | +74.18% | 252B | ||
| +0.84% | +0.15% | +36.65% | +127.55% | 208B | ||
| Average | +0.34% | +2.08% | +35.27% | +85.59% | 477B | |
| Weighted average by Cap. | +0.25% | +3.26% | +37.54% | +99.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 387M 352M 325M 294M 554M 36.37B 574M 3.91B 1.55B 19.52B 1.45B 1.42B 61.82B | 422M 383M 354M 320M 604M 39.63B 625M 4.26B 1.69B 21.26B 1.58B 1.55B 67.36B |
| Net income | 26.77M 24.32M 22.47M 20.3M 38.31M 2.51B 39.65M 270M 107M 1.35B 100M 98.33M 4.27B | 28.8M 26.17M 24.18M 21.84M 41.21M 2.7B 42.66M 291M 115M 1.45B 108M 106M 4.6B |
| Net Debt | -54.72M -49.71M -45.93M -41.49M -78.29M -5.14B -81.05M -552M -219M -2.76B -205M -201M -8.73B | -115M -105M -96.65M -87.3M -165M -10.81B -171M -1.16B -461M -5.8B -432M -423M -18.38B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















